Natera (NTRA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Eurizon Capital SGR S.p.A. trimmed its position in Natera, Inc. (NASDAQ: NTRA) by 16.5% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institu…

Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve r…

Natera NASDAQ: NTRA CFO Mike Brophy said the company's newly announced $6 billion revenue target for 2029 is achievable with strong execution, as he outlined expectations for its Signatera cancer test and defended the im…

Natera, Inc. ( NTRA ) 2026 UBS Global Healthcare Conference November 9, 2026 8:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - UBS Investment Bank, Res…

Natera, Inc. ( NTRA ) 8th Annual Wolfe Research Healthcare Conference November 10, 2026 12:00 PM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Paige Chamberlain - Wolfe Resea…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) f…

NTRA targets $6B in revenues by 2029 as Signatera testing surges, reimbursement expands and higher investments support its long-term growth strategy.…

Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.…

Candriam S.C.A. cut its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 1.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,048 shares o…

Natera, Inc. (NASDAQ: NTRA - Get Free Report) insider Solomon Moshkevich sold 3,419 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total…

Natera, Inc. (NASDAQ: NTRA - Get Free Report) CEO Steven Chapman sold 3,801 shares of Natera stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total transaction…

Natera, Inc. ( NTRA ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Al…

Natera Inc. (NASDAQ:NTRA) shares are plunging Friday after reporting mixed third-quarter results, with revenue and guidance beating estimates while the loss per share came in wider than analysts expected. Here's what you…

Natera NASDAQ: NTRA raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership.…

During the third quarter, Natera achieved record results. Shares advanced during the quarter as Twilio's voice platform was recognized as a backbone for agentic voice agents. Carpenter Technology is benefiting from incre…

The Alger Concentrated Equity ETF underperformed the Russell 1000 Growth Index during the third quarter of 2026. Microsoft Corporation, Natera, Inc., and Meta Platforms Inc were among the top contributors to performance.…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Solomon Moshkevich has been appointed Chief Executive Officer and a member of the…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026. Recent Financial …

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present important new Signatera data at the Society for Immunotherapy of Cance…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced three peer-reviewed publications in npj Precision Oncology, JAMA Otolaryngology, and A…

Aware Super Pty Ltd as trustee of Aware Super bought a new stake in Natera, Inc. (NASDAQ: NTRA) during a recent quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commis…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has received Medicare coverag…

On CNBC's “Halftime Report Final Trades,” Rob Sechan, founder and managing partner of NewEdge Capital Group, picked eBay Inc. (NASDAQ:EBAY).…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congres…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidne…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Soci…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME's Best…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 18. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

